Yingqiu Z. Qi
Zhengzhou, 450001, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Nanotechnology enabled proximity-induced protein degradation from multiscale bottlenecks to precision therapeutics.
Journal: Advanced drug delivery reviews
Published: February 18, 2026
Lysosome-targeted degradation of leucine-rich alpha-2 glycoprotein 1 enables chemosensitization to 5-fluorouracil in colorectal cancer.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: January 10, 2026
New-generation advanced Nano-PROTACs as potential therapeutic agents in cancer therapy.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: October 05, 2025
Ionizable Nano-PROTAC Overcomes Endosomal Entrapment for Enhanced LRG1 Degradation and Tumor Suppression.
Journal: Angewandte Chemie (International ed. in English)
Published: September 15, 2025
Peptide-drug conjugates in tumor therapy: Current advances and future perspectives.
Journal: Cancer letters
Published: August 15, 2025
Lysosome-Targeting Nanochimeras Attenuating Liver Fibrosis by Interconnected Transforming Growth Factor-β Reduction and Activin Receptor-Like Kinase 5 Degradation.
Journal: ACS nano
Published: July 12, 2025
The pan-cancer analysis of LRG1 and its potential role in kidney renal clear cell carcinoma.
Journal: RSC medicinal chemistry
Published: November 29, 2024
PROTAC based targeted degradation of LRG1 for mitigating corneal neovascularization.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 06, 2024
LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation.
Journal: Nano letters
Published: August 26, 2024
Targeted degradation of LRG1 to attenuate renal fibrosis.
Journal: Asian journal of pharmaceutical sciences
Published: February 20, 2024
Last Updated: 09/26/2026